Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S FEXOFENADINE HYDROCHLORIDE ALLERGY versus TAVIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S FEXOFENADINE HYDROCHLORIDE ALLERGY versus TAVIST.
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY vs TAVIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine release from mast cells and basophils, reducing allergic symptoms.
Antihistamine; selective inverse agonist at histamine H1 receptors, blocking histamine-mediated allergic and inflammatory responses.
Fexofenadine hydrochloride 60 mg orally twice daily or 180 mg orally once daily.
1.34 mg orally twice daily; maximum 8.04 mg/day.
None Documented
None Documented
14.4 hours (range 11-16 hours) in healthy adults; prolonged in renal impairment.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in renal/hepatic impairment.
Primarily fecal (80%) and renal (11%) as unchanged drug.
Renal excretion of metabolites (approx. 60%) and unchanged drug (<5%); biliary/fecal elimination accounts for about 40%.
Category A/B
Category C
Antihistamine
Antihistamine